MSFT Microsoft absorbed heavy analyst revisions this week. The $2.8T software giant held 57% upside to consensus targets despite sinking 23% in 2026. Analysts remained bullish as Iran war volatility hammered tech valuations.
NKE Nike saw major analyst reassessment as the $65B athletic apparel maker plunged 31% year to date. Wall Street now projects 48% upside from current levels. The stock hit oversold territory with RSI falling to 20.
Biotech drew fresh scrutiny. APLS Apellis Pharmaceuticals surged 61% this year yet analysts turned negative with 4% downside targets. The $5.2B drugmaker traded at 87 RSI showing extreme overbought conditions.
PHR Phreesia collapsed 51% in 2026 triggering massive analyst upgrades. The healthcare tech firm now holds 102% upside potential as Wall Street bet on turnaround. RSI crashed to 24 signaling deep oversold levels.
Analysts focused on beaten-down names with reversal potential. Microsoft and Nike dominated mega-cap revision activity while smaller names like Phreesia grabbed contrarian attention. The pattern showed Street strategists positioning for post-war recovery in oversold quality stocks.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
